NCT02713269 2026-04-17
Thermal Ablation and Spine Stereotactic Radiosurgery in Treating Patients With Spine Metastases at Risk for Compressing the Spinal Cord
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
Clinical Trials
183 trialsNCT01590069 2026-04-16
Aerosolized Aldesleukin in Treating Patients With Lung Metastases
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT05470283 2026-04-16
Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT01955460 2026-04-15
Genetically Modified T-Cells Followed by Aldesleukin in Treating Patients With Stage III-IV Melanoma
M.D. Anderson Cancer Center
Phase 1 Active not recruiting
NCT03175432 2026-04-15
Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT05377957 2026-04-15
PROQEM
Leiden University Medical Center
Active not recruiting
NCT07531121 2026-04-15
ctDNA for Risk Stratification in Melanoma
Herlev and Gentofte Hospital
Active not recruiting
NCT02656706 2026-04-13
Adjuvant Nivolumab & Low Dose Ipilimumab for Stage III & Resected Stage IV Melanoma
Brown University
Phase 2 Active not recruiting
NCT03271372 2026-04-13
ADAM
University of Washington
Phase 3 Active not recruiting
NCT04291885 2026-04-09
I-MAT
Melanoma and Skin Cancer Trials Limited
Phase 2 Active not recruiting
NCT04869137 2026-04-08
Neoadjuvant Lenvatinib Plus Pembrolizumab in Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT04792073 2026-04-07
Study of Avelumab and/or Radiation Therapy in People With Advanced Merkel Cell Carcinoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05289193 2026-04-07
CD8+ T Cell Imaging During Pre-surgery Immunotherapy in People With Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT05170334 2026-04-06
Binimetinib Plus Belinostat for Subjects With Metastatic Uveal Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT05703269 2026-04-06
HYPOGRYPHE
Wake Forest University Health Sciences
Phase NA Active not recruiting
NCT05130177 2026-03-31
Zimberelimab (AB122) With TIGIT Inhibitor Domvanalimab (AB154) in PD-1 Relapsed/Refractory Melanoma
University of Pittsburgh
Phase 2 Active not recruiting
NCT04261855 2026-03-27
GoTHAM
Melanoma and Skin Cancer Trials Limited
Phase 1/2 Active not recruiting
NCT05724875 2026-03-27
LANCE
Centre Hospitalier Universitaire Vaudois
Phase NA Active not recruiting
NCT04074096 2026-03-25
BEPCOME-MB
UNICANCER
Phase 2 Active not recruiting
NCT04930783 2026-03-25
NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT06008977 2026-03-25
EX-BOOST
AdventHealth Translational Research Institute
Phase NA Active not recruiting
NCT04744935 2026-03-24
Optical Coherence Tomography Guided Laser Treatment of Basal Cell Carcinoma
University of California, Irvine
Phase NA Active not recruiting
NCT04387084 2026-03-23
Short-term Fasting Prior to PD-1/PD-L1 Inhibitor Therapy for of Advanced or Metastatic Skin Malignancy
University of Southern California
Phase 1 Active not recruiting
NCT00338377 2026-03-20
Lymphodepletion Plus Adoptive Cell Transfer With or Without Dendritic Cell Immunization in Patients With Metastatic Melanoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04899908 2026-03-19
Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases
Brigham and Women's Hospital
Phase 2 Active not recruiting
NCT06075589 2026-03-19
Psychoeducation for Uveal Melanoma
Jonsson Comprehensive Cancer Center
Phase NA Active not recruiting
NCT04007744 2026-03-18
Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors
Mayo Clinic
Phase 1 Active not recruiting
NCT02068586 2026-03-16
Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma
Thomas Jefferson University
Phase 2 Active not recruiting
NCT03071406 2026-03-11
Randomized Study of Nivolumab+Ipilimumab+/- SBRT for Metastatic Merkel Cell Carcinoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT03074513 2026-03-11
Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT04478318 2026-03-10
Comparison of Imaging Characteristics of uEXPLORER and Conventional PET/CT in Patients With Lung Cancer, Lymphoma, and Melanoma
University of California, Davis
Phase NA Active not recruiting
NCT03999749 2026-03-09
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Phase 2 Active not recruiting
NCT04020809 2026-03-09
Neoadjuvant Atezolizumab in Cutaneous Melanoma
The Methodist Hospital Research Institute
Phase 1 Active not recruiting
NCT00835133 2026-03-06
Collecting Blood and Tissue Samples From Family Members of Patients With Pancreatic Diseases, Pancreatic Cancer, and Melanoma
Mayo Clinic
Active not recruiting
NCT04940299 2026-03-06
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT00542373 2026-03-05
Widefield Fluorescence and Reflectance Imaging Systems and Oral Tissue Samples in Monitoring Participants at Risk for Developing Oral Cancer
M.D. Anderson Cancer Center
Phase NA Active not recruiting
NCT01644591 2026-03-05
Stereotactic Radiosurgery in Treating Patients With Greater Than 3 Melanoma Brain Metastases
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT06416085 2026-03-05
Psilocybin-assisted Existential, Attachment and RelationaL (PEARL) Therapy for Patients With Advanced Cancer
University Health Network, Toronto
Phase 2 Active not recruiting
NCT04091750 2026-03-03
Nivolumab/Ipilimumab Plus Cabozantinib in Patients With Unresectable Advanced Melanoma
Georgetown University
Phase 2 Active not recruiting
NCT02721459 2026-03-02
XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 1 Active not recruiting
NCT04990726 2026-02-27
Immune Related Toxicity and Symptom Burden in Chronic Cancer Survivors With Melanoma Receiving Adjuvant Immunotherapy With Immune Checkpoint Inhibitors
M.D. Anderson Cancer Center
Active not recruiting
NCT05869539 2026-02-27
BaseTIL-03M
University Hospital, Basel, Switzerland
Phase 1 Active not recruiting
NCT03565783 2026-02-25
Cemiplimab in Treating Patients With Recurrent and Resectable Stage II-IV Head and Neck Cutaneous Squamous Cell Cancer Before Surgery
M.D. Anderson Cancer Center
Phase 2 Active not recruiting
NCT07428252 2026-02-25
Gastrointestinal Microbiome and Response to Immunotherapy in Metastatic Malignant Melanoma
Institute of Oncology Ljubljana
Phase NA Active not recruiting
NCT05176470 2026-02-24
Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients
Ohio State University Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04971499 2026-02-20
A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma
Duke University
Phase 1/2 Active not recruiting
NCT05488483 2026-02-19
A Study of Tumor Imaging With Multispectral Optoacoustic Tomography
Memorial Sloan Kettering Cancer Center
Active not recruiting
NCT06237881 2026-02-18
A Phase 1/2 Study of KSQ-001EX, Autologous Tumor Infiltrating Lymphocytes Engineered to Inactivate the SOCS1 Gene, in Patients With Select Advanced Solid Tumors
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT05912244 2026-02-17
A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Active not recruiting
NCT02231775 2026-02-13
Dabrafenib and Trametinib Before and After Surgery in Treating Patients With Stage IIIB-C Melanoma With BRAF V600 Mutation
M.D. Anderson Cancer Center
Phase 2 Active not recruiting